#1 Clinical Trials Search in Europe

Lecanemab

Lecanemab, also known as BAN2401, is an investigational drug being studied in clinical trials for the treatment of Alzheimer’s disease. This article explores the ongoing research into lecanemab’s safety, efficacy, and potential benefits for patients with early-stage Alzheimer’s disease and those at risk of developing the condition.

Table of Contents

What is Lecanemab?

Lecanemab, also known by its other names BAN2401 and LEQEMBI, is a new medication being studied for the treatment of Alzheimer’s disease[1][2]. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-made proteins designed to target specific substances in the body[3].

How Lecanemab Works

Lecanemab works by targeting and removing a protein called amyloid beta from the brain. In Alzheimer’s disease, amyloid beta builds up and forms plaques, which are thought to contribute to the damage and death of brain cells. By removing these plaques, lecanemab aims to slow down the progression of the disease[4].

Conditions Treated by Lecanemab

Lecanemab is primarily being studied for the treatment of:

  • Early Alzheimer’s Disease: This includes people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia[5].
  • Preclinical Alzheimer’s Disease: This refers to people who have brain changes associated with Alzheimer’s but haven’t yet developed symptoms[6].
  • Dominantly Inherited Alzheimer’s Disease: A rare form of Alzheimer’s caused by genetic mutations[7].

How Lecanemab is Administered

Lecanemab is typically administered in the following ways:

  • Intravenous (IV) Infusion: The drug is given directly into a vein, usually every two weeks[5].
  • Subcutaneous (SC) Injection: Some studies are exploring giving lecanemab as an injection under the skin[2].
The dose and frequency may vary depending on the specific study or treatment plan.

Ongoing Clinical Trials

Several clinical trials are currently underway to evaluate lecanemab’s effectiveness and safety:

  • AHEAD 3-45 Study: This study is looking at lecanemab in people with preclinical Alzheimer’s disease[6].
  • Clarity AD Study: This trial is evaluating lecanemab in people with early Alzheimer’s disease[4].
  • DIAN-TU Study: This study is focusing on people with dominantly inherited Alzheimer’s disease[7].

Efficacy of Lecanemab

Early results from clinical trials suggest that lecanemab may be effective in:

  • Reducing amyloid plaques in the brain[4].
  • Slowing cognitive decline, as measured by tests like the Clinical Dementia Rating-Sum of Boxes (CDR-SB)[4].
  • Potentially delaying the onset of symptoms in people at risk for Alzheimer’s disease[6].
However, it’s important to note that research is ongoing, and more data is needed to fully understand the long-term benefits of lecanemab.

Safety and Side Effects

As with any medication, lecanemab can cause side effects. Researchers are carefully monitoring for:

  • Adverse events (AEs) and serious adverse events (SAEs)[1].
  • Changes in laboratory values, vital signs, and brain imaging results[2].
  • Development of antibodies against the drug (anti-drug antibodies)[2].
Common side effects and their frequency are still being determined through ongoing clinical trials.

Future Research and Potential

Researchers are exploring several aspects of lecanemab’s potential:

  • Combination Therapy: Some studies are looking at using lecanemab in combination with other drugs that target different aspects of Alzheimer’s disease[7].
  • Long-term Effects: Ongoing studies aim to understand the long-term benefits and safety of lecanemab treatment[5].
  • Different Administration Methods: Researchers are exploring various ways to give lecanemab, including subcutaneous injections, which could make treatment more convenient[2].

Aspect Details
Drug Name Lecanemab (also known as BAN2401)
Target Condition Early Alzheimer’s Disease, Preclinical Alzheimer’s Disease
Mechanism of Action Anti-amyloid monoclonal antibody targeting amyloid plaques in the brain
Administration Methods Intravenous infusion, Subcutaneous injection
Dosing Regimens Various, including biweekly and monthly administrations
Primary Outcomes Changes in cognitive function, amyloid levels, biomarkers
Safety Assessments Adverse events, laboratory values, vital signs, MRI findings
Study Durations 18 months to 5+ years (including extension phases)
Notable Features Some trials include long-term extension phases and adaptive designs

FAQ

  • What is lecanemab? Lecanemab is an experimental drug designed to target and remove amyloid plaques in the brain, which are believed to contribute to the progression of Alzheimer's disease.
  • How is lecanemab administered? Lecanemab is typically administered as an intravenous (IV) infusion or subcutaneous injection. The frequency of administration varies depending on the specific clinical trial, ranging from every two weeks to once a month.
  • What types of Alzheimer's patients are being studied in lecanemab trials? Clinical trials are focusing on patients with early Alzheimer's disease, including those with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia. Some studies also include individuals with preclinical Alzheimer's disease who are at risk of developing symptoms.
  • What are the primary outcomes being measured in lecanemab trials? The trials are measuring various outcomes, including changes in cognitive function, daily living activities, brain amyloid levels, and biomarkers associated with Alzheimer's disease. Safety and tolerability of the drug are also key focuses of the studies.
  • How long do lecanemab clinical trials typically last? The duration of lecanemab trials varies, with core studies often lasting 18 months to 4 years. Some trials include extension phases that can last up to 5 years or more to assess long-term effects and safety.

Ongoing Clinical Trials on Lecanemab

  • Study on Lecanemab and Drug Combination for Patients with Early Onset Alzheimer’s Disease Due to Genetic Mutation

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Ireland Italy The Netherlands Spain

  • Study of BAN2401 (lecanemab) in people with early stage Alzheimer’s disease to evaluate its effectiveness in preventing disease progression

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study of Lecanemab (BAN2401) Treatment in People with Early Alzheimer’s Disease: Testing Safety and Effectiveness Over 18 Months

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain Sweden

  • Study on Lecanemab for Patients with Dominantly Inherited Alzheimer’s Disease to Evaluate Prevention and Progression

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Amyloid: A protein that can build up in the brain, forming plaques that are associated with Alzheimer's disease.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track disease progression or treatment effects.
  • Clinical Dementia Rating – Sum of Boxes (CDR-SB): A scale used to measure the severity of dementia symptoms across various cognitive and functional domains.
  • Cerebrospinal fluid (CSF): The clear, colorless fluid that surrounds the brain and spinal cord, often analyzed for biomarkers of Alzheimer's disease.
  • Positron Emission Tomography (PET): An imaging technique used to visualize and measure biological processes in the body, including amyloid buildup in the brain.
  • Preclinical Alzheimer's Disease: A stage where individuals have brain changes associated with Alzheimer's but have not yet developed noticeable symptoms.
  • Mild Cognitive Impairment (MCI): A condition characterized by a slight but noticeable decline in cognitive abilities, which may progress to Alzheimer's disease.
  • Volumetric Magnetic Resonance Imaging (vMRI): A technique used to measure the volume of brain structures, which can help track changes associated with Alzheimer's disease.
  • Alzheimer's Disease Composite Score (ADCOMS): A measurement tool that combines items from various cognitive and functional assessments to evaluate Alzheimer's disease progression.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References

  1. https://clinicaltrials.gov/study/NCT05045716
  2. https://clinicaltrials.gov/study/NCT05533801
  3. https://clinicaltrials.gov/study/NCT05925621
  4. https://clinicaltrials.eu/trial/study-on-the-effects-of-lecanemab-in-patients-with-early-alzheimers-disease/
  5. https://clinicaltrials.gov/study/NCT01767311
  6. https://clinicaltrials.eu/trial/study-on-the-effects-of-lecanemab-in-patients-with-early-preclinical-alzheimers-disease/
  7. https://clinicaltrials.gov/study/NCT05269394